Lucentis contains the active ingredient ranibizumab. It is only available with a doctor’s prescription.
Lucentis is used to treat damage to the retina, which is the inside back wall of your eyeball. It stops the abnormal growth new blood vessels in the retina, and stops any blood vessels leaking. These are problems in eye conditions such as wet age-related macular oedema and macular oedema.
Lucentis is only available as an injection. It is given by your eye specialist into your eye under local anaesthetic, usually once every month.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Lucentis (ranibizumab) is indicated in adults for:,- the treatment of neovascular (wet) age-related macular degeneration (AMD).,- the treatment of visual impairment due to choroidal neovascularisation.,- the treatment of visual impairment due to choroidal neovascularisation (CNV) secondary to pathologic myopia (PM).,- the treatment of visual impairment due to diabetic macular oedema (DME).,- the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (RVO).
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.